Health Canada approves HIV drug Truvada as PrEP treatment in Canada

In a press release issued on February 29, 2016, Gilead Sciences Inc announced Health Canada has approved Truvada® for use as pre-exposure prophylaxis, commonly known as PrEP, to reduce the risk of HIV infection in Canada.

While news of Health Canada’s approval was positively received, access to the treatment is still a concern due to the cost of treatment and the current limit of existing insurance coverage.  Xtra reported on the approval few days before the announcement, and PositiveLite.com published an article which includes community reaction to the news.